{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-03T13:57:56.754907+00:00","company":{"ticker":"OGN","cik":1821825,"company_name":"Organon & Co."},"pagination":{"limit":100,"returned":7,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"3f7bc8b5cb1834fea6151a250f6d78e41381d2a8","cik":1821825,"ticker":"OGN","company_name":"Organon & Co.","filed_at":"2026-04-30T23:59:59+00:00","payload":{"eps_text":"$0.55","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$146 million","period_text":"quarter ended March 31, 2026","report_date":"2026-04-30","result_type":"reported_results","revenue_text":"$1.460 billion"},"claim":"Organon & Co. reported quarter ended March 31, 2026 results: revenue $1.460 billion, net income $146 million, EPS $0.55.","evidence_excerpt":"Organon Reports Results for the First Quarter Ended March 31, 2026 · First quarter 2026 revenue of $1.460 billion, down 4% as-reported and down 9% excluding the impact of foreign currency. · First quarter 2026 diluted earnings per share of $0.55 and non-GAAP Adjusted diluted earnings per share of $0.71. · First quarter 2026 net income of $146 million and Adjusted EBITDA (non-GAAP) of $415 million, representing an Adjusted EBITDA margin of 28.4%.","confidence":0.98,"filing_url":"https://secwatch.observer/filing/0001104659-26-052165","anchor_url":"https://secwatch.observer/filing/0001104659-26-052165#claim-3f7bc8b5cb1834fea6151a250f6d78e41381d2a8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1821825/000110465926052165/0001104659-26-052165-index.htm"},{"fact_type":"material_agreement","fact_key":"85a8e508818ea768029699bf901ddcb580e84024","cik":1821825,"ticker":"OGN","company_name":"Organon & Co.","filed_at":"2026-04-27T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Agreement and Plan of Merger","agreement_type":"merger","counterparty":"Sun Pharmaceutical Holdings USA, Inc., Sun Pharma America, Inc., Sun Pharmaceutical Industries Limited, Sun Pharma Canada Inc., Sun Pharma (Netherlands) B.V.","effective_date":"2026-04-26","item_codes_triggered":["1.01"],"value_text":null},"claim":"Organon & Co. entered into Agreement and Plan of Merger with Sun Pharmaceutical Holdings USA, Inc., Sun Pharma America, Inc., Sun Pharmaceutical Industries Limited, Sun Pharma Canada Inc., Sun Pharma (Netherlands) B.V. (effective 2026-04-26).","evidence_excerpt":"On April 26, 2026, Organon & Co. (the “ Company ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Sun Pharmaceutical Holdings USA, Inc., a Delaware corporation (“ Parent ”), Sun Pharma America, Inc., a Delaware corporation and wholly owned subsidiary of Parent and/or its affiliates (“ Merger Sub ”) and, solely for the purposes of certain covered provisions of the Merger Agreement, Sun Pharmaceutical Industries Limited, an entity organized under the laws of India (“ India Parent ”), Sun Pharma Canada Inc., a corporation incorporated under the laws of the Province of Ontario and Sun Pharma (Netherlands) B.V., a private company with limited liability incorporated under the laws of the Netherlands, pursuant to which, among other things, Merger Sub will merge with and into the Company (the “ Merger ”), with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001193125-26-178718","anchor_url":"https://secwatch.observer/filing/0001193125-26-178718#claim-85a8e508818ea768029699bf901ddcb580e84024","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1821825/000119312526178718/0001193125-26-178718-index.htm"},{"fact_type":"executive_change","fact_key":"b97143d3c6","cik":1821825,"ticker":"OGN","company_name":"Organon & Co.","filed_at":"2025-04-15T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2025-07-01","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Ramona A. Sequeira was appointed as Director at Organon & Co..","evidence_excerpt":"the appointment of Ramona A. Sequeira will become immediately effective to fill the resulting vacancy.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-035173","anchor_url":"https://secwatch.observer/filing/0001104659-25-035173#claim-b97143d3c6","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1821825/000110465925035173/0001104659-25-035173-index.htm"},{"fact_type":"executive_change","fact_key":"b104a24572","cik":1821825,"ticker":"OGN","company_name":"Organon & Co.","filed_at":"2025-01-21T23:59:59+00:00","payload":{"action":"ceased performing her functions","action_category":"departure","departure_tone":"not_disclosed","effective_date":"2025-01-15","interim":false,"role":"Chief Commercial Officer","role_category":"other_named_officer","successor_name":null,"successor_named":false},"claim":"Susanne Fiedler departed as Chief Commercial Officer at Organon & Co..","evidence_excerpt":"On January 15, 2025, Organon & Co. (the “ Company ”) announced that effective January 15, 2025, Susanne Fiedler ceased performing her functions as Chief Commercial Officer.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001104659-25-004711","anchor_url":"https://secwatch.observer/filing/0001104659-25-004711#claim-b104a24572","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1821825/000110465925004711/0001104659-25-004711-index.htm"},{"fact_type":"material_agreement","fact_key":"9026942894e70f6a8d55cc8c3b2fc6505761f009","cik":1821825,"ticker":"OGN","company_name":"Organon & Co.","filed_at":"2024-05-17T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Amendment No. 2 to Senior Secured Credit Agreement and Amendment to Security Agreement","agreement_type":"credit_facility","counterparty":"JPMorgan Chase Bank, N.A., as administrative agent and collateral agent","effective_date":"2024-05-17","item_codes_triggered":["1.01"],"value_text":"amendment to existing senior secured credit facilities: extended maturity of Dollar Term Facility to"},"claim":"Organon & Co. entered into Amendment No. 2 to Senior Secured Credit Agreement and Amendment to Security Agreement with JPMorgan Chase Bank, N.A., as administrative agent and collateral agent valued at amendment to existing senior secured credit facilities: extended maturity of Dollar Term Facility to (effective 2024-05-17).","evidence_excerpt":"On May 17, 2024, the Companies entered into Amendment No. 2 to Senior Secured Credit Agreement and Amendment to Security Agreement (the “ Credit Agreement Amendment ”), by and among the Companies as borrowers, the Subsidiary Guarantors, the lenders party thereto and JPMorgan Chase Bank, N.A., as administrative agent and collateral agent.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-063008","anchor_url":"https://secwatch.observer/filing/0001104659-24-063008#claim-9026942894e70f6a8d55cc8c3b2fc6505761f009","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1821825/000110465924063008/0001104659-24-063008-index.htm"},{"fact_type":"material_agreement","fact_key":"8172e6e35c80a8e5427748f550c586ecf640d7fc","cik":1821825,"ticker":"OGN","company_name":"Organon & Co.","filed_at":"2024-05-17T23:59:59+00:00","payload":{"action":"entry","agreement_name":"Indentures for 6.750% Senior Secured Notes due 2034 and 7.875% Senior Unsecured Notes due 2034","agreement_type":"notes_offering","counterparty":"U.S. Bank Trust Company, National Association","effective_date":"2024-05-17","item_codes_triggered":["1.01"],"value_text":"two series of notes totaling $1,000,000,000 principal amount: $500,000,000 6.750% senior secured not"},"claim":"Organon & Co. entered into Indentures for 6.750% Senior Secured Notes due 2034 and 7.875% Senior Unsecured Notes due 2034 with U.S. Bank Trust Company, National Association valued at two series of notes totaling $1,000,000,000 principal amount: $500,000,000 6.750% senior secured not (effective 2024-05-17).","evidence_excerpt":"On May 17, 2024, Organon & Co. (the “ Company ”) and Organon Foreign Debt Co-Issuer B.V., a Dutch private limited liability company ( besloten vennootschap met beperkte aansprakelijkheid ) and wholly-owned subsidiary of Organon (the “ Co-Issuer ”, and together with the Company, the “ Companies ”), closed their previously announced private offering (the “ Notes Offering ”) of $500 million of 6.750% senior secured notes due 2034 (the “ Secured Notes ”) and $500 million of 7.875% senior unsecured notes due 2034 (the “ Unsecured Notes ” and, together with the Secured Notes, the “ Notes ”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-063008","anchor_url":"https://secwatch.observer/filing/0001104659-24-063008#claim-8172e6e35c80a8e5427748f550c586ecf640d7fc","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1821825/000110465924063008/0001104659-24-063008-index.htm"},{"fact_type":"earnings_release","fact_key":"d9d1f565c930bb2a8fd2facf870b95f623f0254e","cik":1821825,"ticker":"OGN","company_name":"Organon & Co.","filed_at":"2024-05-02T23:59:59+00:00","payload":{"eps_text":"$0.78","guidance_signal":"reaffirmed","item_codes_triggered":["2.02"],"net_income_text":"$201 million","period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-02","result_type":"reported_results","revenue_text":"$1,622 million"},"claim":"Organon & Co. reported the first quarter ended March 31, 2024 results: revenue $1,622 million, net income $201 million, EPS $0.78. Guidance reaffirmed.","evidence_excerpt":"First quarter 2024 revenue of $1,622 million, up 5% on an as-reported basis and 7% at constant currency • First quarter 2024 diluted earnings per share of $0.78 and non-GAAP Adjusted diluted earnings per share of $1.22; both reported and non-GAAP Adjusted diluted earnings per share include $15 million expense, or $(0.05) per share, for acquired in-process research and development (IPR&D) and milestones • First quarter 2024 net income of $201 million and Adjusted EBITDA (non-GAAP) of $538 million • Full year 2024 financial guidance ranges affirmed","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001104659-24-056017","anchor_url":"https://secwatch.observer/filing/0001104659-24-056017#claim-d9d1f565c930bb2a8fd2facf870b95f623f0254e","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1821825/000110465924056017/0001104659-24-056017-index.htm"}]}